Ronald C. Hendrickson

Ronald C. Hendrickson

Auto-generated profile, based on publicly available information

Ronald C. Hendrickson

Microchemistry and Proteomics Core Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2017 in Science
Verified
Journal Article
Closed access
PDF file
ETEneda Toska
Eneda Toska
Hatice Ulku OsmanbeyogluHatice Ulku Osmanbeyoglu
Hatice Ulku Osmanbeyoglu
PCPau Castel
Pau Castel
CCCarmen Chan
Carmen Chan
RHRonald C. Hendrickson
Ronald C. Hendrickson
JBJosé Baselga
José Baselga
Activating mutations in PIK3CA, the gene encoding phosphoinositide-(3)-kinase α (PI3Kα), are frequently found in estrogen receptor (ER)–positive breast cancer. PI3Kα inhibitors, now in late-stage clinical development, elicit a robust compensatory increase in ER-dependent transcription that limits therapeutic efficacy. We investigated the chromatin-based mechanisms leading to the activation of ER upon PI3Kα inhibition. We found that PI3Kα inhibition mediates an open chromatin state at the ER target loci in breast cancer models and clinical samples. KMT2D, a histone H3 lysine 4 methyltransferase, is required for FOXA1, PBX1, and ER recruitment and activation. AKT binds and phosphorylates KMT2D, attenuating methyltransferase activity and ER function, whereas PI3Kα inhibition enhances KMT2D activity. These findings uncover a mechanism that controls the activation of ER by the posttranslational modification of epigenetic regulators, providing a rationale for epigenetic therapy in ER-positive breast cancer.